A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells

Cell Cycle

Volumn 13, Issue 19, 2014, Pages 3143-3149

  Zhang, Jianliang ^a   He, Di Hua ^b   Zajac Kaye, Maria ^b   Hochwald, Steven N ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Akt; Cancer growth; Fak inhibitor; PDAC; Signal

Indexed keywords

FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GSK 2256098; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; GSK2256098; HYDROXAMIC ACID; PROTEIN KINASE INHIBITOR;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; CELL MOTION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADENOCARCINOMA; AMINOPYRIDINES; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; HYDROXAMIC ACIDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84927138265     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.949550     Document Type: Article

References (21)

1. Guillaumond F, Iovanna JL, Vasseur S. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways. Arch Biochem Biophys 2014; 545:69-73; PMID:24393743; http://dx.doi.org/10.1016/j.abb.2013.12.019
2. Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006; 66:10525-33; PMID:17079475; http://dx.doi.org/10.1158/0008-5472.CAN-06-2387
3. Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int 2014; 64:10-9; PMID:24471965; http://dx.doi.org/10.1111/pin.12114
4. Preis M, Korc M. Signaling pathways in pancreatic cancer. Crit Rev Eukar Gene Exp 2011; 21:115-29; PMID:22077151; http://dx.doi.org/10.1615/CritRevEukarGeneExpr.v21.i2.20
5. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, Cheresh DA. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009; 15:1163-9; PMID:19734908; http://dx.doi.org/10.1038/nm.2009
6. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Nat Cancer Inst 2000; 92:1065-73; PMID:10880549; http://dx.doi.org/10.1093/jnci/92.13.1065
7. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29:1096-107; PMID:18263593; http://dx.doi.org/10.1093/carcin/bgn026
8. Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, et al. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle 2012; 11:3250-9; PMID:22894899; http://dx.doi.org/10.4161/cc.21611
9. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009; 8:2435-43; PMID:19571674; http://dx.doi.org/10.4161/cc.8.15.9145
10. Ucar DA, Dang LH, Hochwald SN. Focal adhesion kinase signaling and function in pancreatic cancer. Front Biosci (Elite Ed) 2011; 3:750-6; PMID:21196348; http://dx.doi.org/10.2741/e283
11. Zhang J, Hochwald SN. The role of FAK in tumor metabolism and therapy. Pharmacol Ther 2014; 142:154-63; PMID:24333503; http://dx.doi.org/10.1016/j.pharmthera.2013.12.003
12. Schultze A, Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anti-Cancer Agent Med Chem 2011; 11:593-9; PMID:21787277; http://dx.doi.org/10.2174/187152011796817727
13. Soria J-C, Arkenau H-T, Blagden SP, Plummer R, Ranson M, Evans TRJ, Zalcman G, Bahleda R, Hollebecque A, Lemech C, et al. Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors. J Clin Oncol: Off J Am Soc Clin Oncol 2012; 30:abstr 3000
14. Auger KR, Smitheman KN, Korenchuk S, McHugh C, Kruger R, Aller GSV, Smallwood A, Gontarek RR, Faitg T, Johnson N. The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer. Eur J Cancer 2012; 48:118; http://dx.doi.org/10.1016/S0959-8049(12)72185-8
15. Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ, Lee JC, Shen TL. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol 2010; 177:1629-37; PMID:20724588; http://dx.doi.org/10.2353/ajpath.2010.100172
16. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer J Int Du Cancer 1977; 19:128-35; PMID:832918; http://dx.doi.org/10.1002/ijc.2910190118
17. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer J Int Du Cancer 1975; 15:741-7; PMID:1140870; http://dx.doi.org/10.1002/ijc.2910150505
18. Owens RB, Smith HS, Nelson-Rees WA, Springer EL. Epithelial cell cultures from normal and cancerous human tissues. J Nat Cancer Inst 1976; 56:843-9; PMID:176412
19. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, Berjian R, Douglass HO, Martin EW, Chu TM. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In vitro 1982; 18:24-34; PMID:7182348; http://dx.doi.org/10.1007/BF02796382
20. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999; 1:50-62; PMID:10935470; http://dx.doi.org/10.1038/sj.neo.7900005
21. Loor R, Nowak NJ, Manzo ML, Douglass HO, Chu TM. Use of pancreas-specific antigen in immunodiagnosis of pancreatic cancer. Clin Lab Med 1982; 2:567-78; PMID:6754226